Inogen Inc (INGN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Inogen Inc stock (INGN) is currently trading at $6.42. Inogen Inc PS ratio (Price-to-Sales) is 0.48. Analyst consensus price target for INGN is $13.00. WallStSmart rates INGN as Underperform.
- INGN PE ratio analysis and historical PE chart
- INGN PS ratio (Price-to-Sales) history and trend
- INGN intrinsic value — DCF, Graham Number, EPV models
- INGN stock price prediction 2025 2026 2027 2028 2029 2030
- INGN fair value vs current price
- INGN insider transactions and insider buying
- Is INGN undervalued or overvalued?
- Inogen Inc financial analysis — revenue, earnings, cash flow
- INGN Piotroski F-Score and Altman Z-Score
- INGN analyst price target and Smart Rating
Inogen Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Inogen Inc (INGN) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, eps growth. Concerns around market cap and peg ratio. Mixed signals suggest waiting for clearer direction before acting.
Inogen Inc (INGN) Key Strengths (4)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Earnings per share surging 87.30% year-over-year
76.87% of shares held by major funds and institutions
Supporting Valuation Data
Inogen Inc (INGN) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive relative to growth, significant premium
Revenue growing slowly at 2.00% annually
Micro-cap company with very limited liquidity and high volatility
Inogen Inc (INGN) Detailed Analysis Report
Overall Assessment
This company scores 49/100 in our Smart Analysis, earning a D+ grade. Out of 10 metrics analyzed, 4 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book, EPS Growth. Valuation metrics including Price/Sales (0.48), Price/Book (0.86) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 87.30%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including PEG Ratio (3.48) suggest expensive pricing. Growth concerns include Revenue Growth at 2.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -12.40%, Operating Margin at -12.20%, Profit Margin at -6.52%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -12.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 2.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
INGN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
INGN's Price-to-Sales ratio of 0.48x trades at a deep discount to its historical average of 5.82x (5th percentile). The current valuation is 98% below its historical high of 28.83x set in Aug 2018, and 59% above its historical low of 0.3x in Oct 2023. Over the past 12 months, the PS ratio has compressed from ~0.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Inogen Inc (INGN) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Inogen Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 349M with 200% growth year-over-year. The company is currently unprofitable, posting a -6.5% profit margin.
Key Findings
Revenue growing at 200% YoY, reaching 349M. This pace significantly outperforms most MEDICAL DEVICES peers.
Debt-to-equity ratio of 0.09 indicates a conservative balance sheet with 108M in cash.
The company is unprofitable with a -6.5% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Inogen Inc maintain 200%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.78, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Inogen Inc.
Bottom Line
Inogen Inc is a high-conviction growth story with revenue accelerating at 200% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -6.5% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(54 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:28:30 AM
About Inogen Inc(INGN)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other physicians, and third-party payers in the United States and internationally. The company is headquartered in Goleta, California.